Abstract
Thalidomide and its immunomodulatory derivatives have provided the most significant advance in the therapy of myeloma since the introduction of high dose chemotherapy followed by stem cell transplantation nearly 20 years ago. The mechanism of action of thalidomide is complex and involves many aspects of malignant plasma cell growth and bone marrow stromal cell microenvironment interaction. Thalidomide was first used because of its anti-angiogenic properties, however it is the immunomodulatory actions that involve increasing host tumour-specific immunosurveillance by both T cell and natural killer cells which may be the most important mode of action.
Keywords: Anti-Angiogenic, immunomodulatory, bone marrow microenvironment, T cell, cytomegalovirus (CMV)
Current Cancer Drug Targets
Title: The Use of Thalidomide in Myeloma Therapy as an Effective Anticancer Drug
Volume: 6 Issue: 4
Author(s): Daniel M.-Y. Sze, Ross Brown, Shihong Yang, P. J. Ho, John Gibson and Douglas Joshua
Affiliation:
Keywords: Anti-Angiogenic, immunomodulatory, bone marrow microenvironment, T cell, cytomegalovirus (CMV)
Abstract: Thalidomide and its immunomodulatory derivatives have provided the most significant advance in the therapy of myeloma since the introduction of high dose chemotherapy followed by stem cell transplantation nearly 20 years ago. The mechanism of action of thalidomide is complex and involves many aspects of malignant plasma cell growth and bone marrow stromal cell microenvironment interaction. Thalidomide was first used because of its anti-angiogenic properties, however it is the immunomodulatory actions that involve increasing host tumour-specific immunosurveillance by both T cell and natural killer cells which may be the most important mode of action.
Export Options
About this article
Cite this article as:
Sze M.-Y. Daniel, Brown Ross, Yang Shihong, Ho J. P., Gibson John and Joshua Douglas, The Use of Thalidomide in Myeloma Therapy as an Effective Anticancer Drug, Current Cancer Drug Targets 2006; 6 (4) . https://dx.doi.org/10.2174/156800906777441762
DOI https://dx.doi.org/10.2174/156800906777441762 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulatory T Cells in Cancer Biology: A Possible New Target for Biochemical Therapies
Mini-Reviews in Medicinal Chemistry The Influence of Thyroid Hormone on Ca<sup>2+</sup> Signaling Pathways During Embryonal Development
Current Topics in Medicinal Chemistry Glycation and Hypoxia: Two Key Factors for Adipose Tissue Dysfunction
Current Medicinal Chemistry Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Dietary Toxins, Endoplasmic Reticulum (ER) Stress and Diabetes
Current Diabetes Reviews Molecular and Biochemical Changes of the Cardiovascular System due to Smoking Exposure
Current Pharmaceutical Design Aspartic Proteases in Drug Discovery
Current Pharmaceutical Design Behavioral and Neurochemical Studies in Distinct Animal Models of Ethanols Motivational Effects
Current Drug Abuse Reviews Topical Application of <i>In Vitro</i> Transcribed mRNA to the Airways as a Novel Gene Therapy Approach for the Treatment of Cystic Fibrosis
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design Interaction of Nerve Agent Antidotes with Cholinergic Systems
Current Medicinal Chemistry In Vitro Regulatory Effect of Epididymal Serpin CRES on Protease Activity of Proprotein Convertase PC4/PCSK4
Current Molecular Medicine VIP in Neurological Diseases: More Than A Neuropeptide
Endocrine, Metabolic & Immune Disorders - Drug Targets “PARG Inhibitors’ Success: A Long Way to Go!”
Current Enzyme Inhibition Role of Trim5α in the Suppression of Cross-Species Transmission and its Defence Against Human Immunodeficiency Virus
Current HIV Research Disorders of Mineral Metabolism in the Newborn
Current Pediatric Reviews GPCR Drug Discovery: Novel Ligands for CNS Receptors
Recent Patents on CNS Drug Discovery (Discontinued) Reproductive Toxicity of T Cells in Early Life: Abnormal Immune Development and Postnatal Diseases
Current Drug Targets Critical Appraisal of Ex Vivo Expansion of Human Limbal Epithelial Stem Cells
Current Molecular Medicine Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties
Protein & Peptide Letters